Peripheral T cell lymphomas: from the bench to the clinic. Review uri icon

Overview

abstract

  • Peripheral T cell lymphomas (PTCLs) are a heterogeneous group of orphan neoplasms. Despite the introduction of anthracycline-based chemotherapy protocols, with or without autologous haematopoietic transplantation and a plethora of new agents, the progression-free survival of patients with PTCLs needs to be improved. The rarity of these neoplasms, the limited knowledge of their driving defects and the lack of experimental models have impaired clinical successes. This scenario is now rapidly changing with the discovery of a spectrum of genomic defects that hijack essential signalling pathways and foster T cell transformation. This knowledge has led to new genomic-based stratifications, which are being used to establish objective diagnostic criteria, more effective risk assessment and target-based interventions. The integration of genomic and functional data has provided the basis for targeted therapies and immunological approaches that underlie individual tumour vulnerabilities. Fortunately, novel therapeutic strategies can now be rapidly tested in preclinical models and effectively translated to the clinic by means of well-designed clinical trials. We believe that by combining new targeted agents with immune regulators and chimeric antigen receptor-expressing natural killer and T cells, the overall survival of patients with PTCLs will dramatically increase.

publication date

  • April 6, 2020

Research

keywords

  • Lymphoma, T-Cell, Peripheral
  • Signal Transduction
  • T-Lymphocytes
  • Transcription Factors

Identity

Scopus Document Identifier

  • 85083242382

Digital Object Identifier (DOI)

  • 10.1038/s41568-020-0247-0

PubMed ID

  • 32249838

Additional Document Info

volume

  • 20

issue

  • 6